Media
Publications
Scientific publications, posters and reviews about Gliovac/ERC1671/sitoiganap.
- Jul 2022Cohort Study of GLIOVAC/ERC1671/SITOIGANAP to treat GlioblastomaPDF
- Aug 2018Review - Therapeutic Immunization against Glioblastoma – Virgil SchijnsPDF
- Aug 2018Phase II study of ERC1671/SITOIGANAP plus bevacizumab versus bevacizumab plus placebo in recurrent glioblastoma: interim results and correlations with CD4+ T-lymphocyte counts.PDF
- Jan 2018Therapeutic vaccination against malignant gliomas Q1 based on allorecognition and syngeneic tumor antigens: Proof of principle in two strains of ratPDF
- Oct 2015Use of ERC-1671/SITOIGANAP Vaccine in a patient with Recurrent Glioblastoma Multiforme after Progression during Bevacizumab Therapy: First Published Report.PDF
- May 2015Therapeutic vaccination against malignant gliomas Q1 based on allorecognition and syngeneic tumor antigens: Proof of principle in two strains of rat.PDF
- Apr 2015First clinical results of a personalized immunotherapeutic vaccine against recurrent, incompletely resected, treatment-resistant glioblastoma multiforme (GBM) tumors, based on combined all- and auto-immune tumor reactivity.PDF
- Jul 2012Cancer Immunology.PDF
- May 2012Development of immune memory to glial brain tumors after tumor regression induced by immunotherapeutic Toll-like receptor 7/8 activationPDF
- May 2010Immunotherapy of Malignant Gliomas using autologous and allogeneic tissue cells.PDF
- Jun 2024General Meeting 2024 File 1 of 2PDF
- Jun 2024General Meeting 2024 File 2 of 2PDF
- Jun 2024Invitation_Meeting_English_June__22_2024PDF
- Jun 2024Invitation_Meeting_French_June_22_2024PDF
- Jul 20242024-07-09 Investor Letter EnglishPDF
- Jul 20242024-07-09 Investor Letter FrenchPDF
- Jul 2024General Assembly - June 2024PDF
- Jul 2024Letter from USCPDF
- Jul 202412-2023 LetterPDF
- Jul 2024Letter 07 2024PDF
- Dec 20242025 January ERC MeetingPDF